VERAXA Biotech Secures $27.5 Million Financing and $50 Million Equity Line Ahead of Nasdaq Listing

VERAXA Biotech AG, a portfolio company of Xlife Sciences AG (SIX: XLS), has announced securing $27.5 million in senior secured convertible note financing from High Trail Capital LP and entering into a share purchase agreement with Lincoln Park Capital Fund LLC providing access to up to $50 million in equity financing. These financial arrangements are intended to bolster VERAXA's balance sheet ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market.

The High Trail Capital financing comprises a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share. Meanwhile, the equity line with Lincoln Park Capital provides VERAXA with discretionary access to capital over a 24-month period without warrants or participation rights. The company stated that the combined financing structure supports continued development of its antibody-based therapeutic pipeline, including proprietary BiTAC formats and antibody-drug conjugates.

This funding comes at a critical time as VERAXA prepares to go public. The injection of capital will likely accelerate its drug discovery and development efforts, potentially bringing novel therapies closer to clinical trials. The BiTAC antibody formats represent a promising approach in oncology and other therapeutic areas, leveraging bispecific antibodies to engage immune cells more effectively.

The involvement of High Trail Capital and Lincoln Park Capital, both experienced investors in life sciences, signals confidence in VERAXA's technology and strategy. The equity line facility offers flexibility, allowing the company to draw funds as needed without diluting existing shareholders prematurely.

VERAXA Biotech originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research. The company focuses on antibody drug conjugates (ADCs) and novel antibody-based therapies, applying quality-by-design principles in drug discovery.

For more information on VERAXA Biotech, visit https://www.veraxa.com/. Details on Xlife Sciences can be found at https://www.xlifesciences.ch. The full press release is available at https://ibn.fm/oxUOU.